New Imaging-Guided biopsy aims to improve breast cancer detection

NCT ID NCT04862429

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using contrast-enhanced mammography to guide breast biopsies is more accurate than the standard X-ray-guided method for suspicious calcifications. About 184 women with suspicious calcifications (BIRADS R3-R5) were randomly assigned to one of the two biopsy techniques. The goal was to see if the new method better targets the most dangerous part of the lesion, potentially improving diagnosis and treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
contrast-enhanced mammography guided biopsy
What this could lead to
If successful, this could make breast biopsies more accurate, reducing the need for repeat procedures and improving detection of aggressive cancers.
What could go wrong
This is a completed, moderate-sized study. The technique requires contrast dye, which carries a small risk of allergic reaction or kidney issues. It may not be widely available or change standard practice if results are not clearly superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda USL - IRCCS di Reggio Emilia

    Reggio Emilia, RE, 42123, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.